...
首页> 外文期刊>Urology >Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
【24h】

Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.

机译:膀胱移行细胞癌行根治性膀胱切除术患者血浆尿激酶型纤溶酶原激活剂及其受体与临床结局的关系。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: The urokinase plasminogen activation (uPA) system plays an important role in tumor invasion and metastasis by mediating proteolysis, adhesion, and migration of tumor cells. We tested the hypothesis that preoperative plasma levels of uPA and its specific receptor, uPAR, would predict cancer stage and prognosis in patients with transitional cell carcinoma of the bladder. METHODS: The study group consisted of 51 patients who underwent radical cystectomy for muscle-invasive cancer or Tis, Ta, or T1 transitional cell carcinoma refractory to intravesical therapy and 44 men without cancer. Preoperative plasma levels of uPA and uPAR were measured by enzyme-linked immunosorbent assay in patients with available samples (51 and 38, respectively) and correlated with the clinical and pathologic characteristics and clinical outcome. RESULTS: Plasma uPA and uPAR levels were both greater in those with bladder cancer than in the healthy subjects (P <0.001). Plasma uPAR levels were greatest in patients with metastases to distant lymph nodes (P = 0.042). Preoperative uPA was independently associated with metastases to regional lymph nodes (P = 0.017), lymphovascular invasion (P = 0.019), disease progression (P = 0.030), and death from bladder cancer (P = 0.038). uPAR was not associated with bladder cancer outcome. CONCLUSIONS: Plasma uPA and uPAR levels were greater in those with bladder cancer compared with healthy controls. For patients with bladder cancer, a greater preoperative plasma uPA level was an independent predictor of poor outcome after radical cystectomy.
机译:目的:尿激酶纤溶酶原激活(uPA)系统通过介导肿瘤细胞的蛋白水解,粘附和迁移在肿瘤侵袭和转移中起重要作用。我们检验了以下假设,即术前血浆uPA及其特异性受体uPAR可以预测膀胱移行细胞癌患者的癌症分期和预后。方法:研究组包括51例因膀胱浸润难治的肌肉浸润性癌或Tis,Ta或T1移行细胞癌接受根治性膀胱切除术的患者和44例无癌的男性。通过酶联免疫吸附测定法在有可用样品(分别为51和38)的患者中测量术前血浆uPA和uPAR的水平,并将其与临床和病理学特征以及临床结果相关联。结果:膀胱癌患者的血浆uPA和uPAR水平均高于健康受试者(P <0.001)。转移至远处淋巴结的患者血浆uPAR水平最高(P = 0.042)。术前uPA与区域淋巴结转移(P = 0.017),淋巴管浸润(P = 0.019),疾病进展(P = 0.030)和膀胱癌死亡(P = 0.038)独立相关。 uPAR与膀胱癌预后无关。结论:与健康对照组相比,膀胱癌患者的血浆uPA和uPAR水平更高。对于膀胱癌患者,术前血浆uPA水平升高是根治性膀胱切除术后不良预后的独立预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号